Search

Author/Creator Forrestal, Fiona

1. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Issue 5 (May 2018)

Authors:
Kapoor, Raju; Ho, Pei-Ran; Campbell, Nolan; Chang, Ih; Deykin, Aaron; Forrestal, Fiona; Lucas, Nisha; Yu, Bei; Arnold, Douglas L; Freedman, Mark S; Goldman, Myla D; Hartung, Hans-Peter; Havrdová, Eva Kubala; Jeffery, Douglas; Miller, Aaron; Sellebjerg, Finn; Cadavid, Diego; Mikol, Dan; Steiner, D...
Journal:
Lancet neurology
Issue:
Volume 17:Issue 5(2018)
Page Start:
405
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Item‐level analysis of clinical measures in patients with early symptomatic Alzheimer's disease following treatment with high‐dose aducanumab in the phase 3 study EMERGE. (31st December 2021)

Authors:
Cohen, Sharon; He, Ping; Benea, Mihaela Levitchi; Miller, Ryan; Forrestal, Fiona; Pang, Menglan; Castrillo‐Viguera, Carmen; Harrison, John E; Jaeger, Judy; Mummery, Catherine J.; Porsteinsson, Anton P.; Cummings, Jeffrey L.; Tian, Ying; Yang, Lili; Haeberlein, Samantha Budd
Journal:
Alzheimer's & dementia
Issue:
Volume 17(2021)Supplement 9
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search